Urogen Pharma $URGN Shares Bought by Truist Financial Corp

Truist Financial Corp increased its holdings in Urogen Pharma (NASDAQ:URGN) by 134.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 72,286 shares of the company’s stock after acquiring an additional 41,436 shares during the quarter. Truist Financial Corp owned approximately 0.16% of Urogen Pharma worth $1,442,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of URGN. Osaic Holdings Inc. increased its holdings in Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares during the last quarter. Strs Ohio acquired a new stake in shares of Urogen Pharma during the third quarter worth approximately $76,000. CWM LLC increased its stake in shares of Urogen Pharma by 18.0% in the third quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after buying an additional 650 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after acquiring an additional 5,571 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Urogen Pharma by 9.4% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company’s stock valued at $127,000 after acquiring an additional 797 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma Trading Up 4.0%

Shares of Urogen Pharma stock opened at $21.35 on Monday. The business’s 50 day simple moving average is $21.96 and its 200-day simple moving average is $20.68. The stock has a market capitalization of $999.39 million, a price-to-earnings ratio of -6.17 and a beta of 1.33. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $30.00.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.03. The company had revenue of $27.48 million for the quarter, compared to analyst estimates of $34.09 million. Sell-side analysts predict that Urogen Pharma will post -3.12 earnings per share for the current year.

Analysts Set New Price Targets

URGN has been the subject of several research analyst reports. D. Boral Capital reissued a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a research report on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Urogen Pharma in a research report on Monday, October 27th. Finally, Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.00.

Insider Buying and Selling at Urogen Pharma

In related news, insider Mark Schoenberg sold 7,373 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $145,174.37. Following the completion of the sale, the insider owned 144,985 shares of the company’s stock, valued at $2,854,754.65. This represents a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.70% of the stock is currently owned by corporate insiders.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.